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Highly active antiretroviral therapy (HAART) has dramatically 
reduced morbidity and mortality among HIV/AIDS patients. 
However, a major drawback of HAART is the development of 
drug resistance.1,2 South Africa has a high HIV prevalence, and 
access to treatment is expanding. A regimen based on the genetic 
resistance profiles of patients’ viruses before initiating therapy 
generally correlates with a better outcome, compared with the 
absence of such resistance data.2 The emergence of drug resistance in 
drug-naïve populations should be monitored, particularly in regions 
such as Limpopo Province, where such data are scarce. We aimed to 
determine the prevalence of ARV drug-resistance among drug-naïve 
HIV-infected individuals in a community where treatment has been 
provided for a considerable time.
Methods
Study subjects were recruited from the HIV/AIDS Wellness Clinic 
in Bela-Bela, Waterberg District, Limpopo Province. Treatment at 
the clinic began in 2001. HIV-positive individuals without prior 
exposure to ARV were recruited sequentially between February 2008 
and December 2008. Five ml of venous blood was collected into 
EDTA vacutainer tubes from each consenting subject. Demographic 
data were obtained by questionnaire administration. Viral RNA 
was isolated using the viral mini RNA kit (Qiagen). Viral DNA was 
synthesised by a one-tube reverse transcription-polymerase chain 
reaction (RT-PCR), followed by a nested PCR.3 The PCR products 
were verified for expected size by electrophoresis of 1% agarose gel. 
PCR amplicons were purified with a QIAquick PCR purification kit 
(Qiagen), and direct population-based sequencing was performed 
on both strands. HIV subtyping was done by phylogenetic analysis. 
Predicted amino acids for the PR and RT genes were aligned using 
the BioEdit programme (http://www.mbio.ncsu.edu/BioEdit/bioedit.
html). Owing to the broad scope of viral mutations, drug-resistant 
mutations were identified using the Stanford HIV Drug Resistance 
Interpretation Algorithm (http://hivdb.stanford.edu/) and the 
International AIDS Society (IAS)–USA Guidelines.4 Two algorithms 
were used to describe as broadly as possible the significance of 
observed amino acid substitutions. The Bayesian analysis was used to 
calculate the 95% confidence interval (CI), to estimate the confidence 
limits around the prevalence estimate. The PR and RT gene sequences 
reported here have been submitted to GenBank with the following 
respective accession numbers: PR [GU139577-GU139633] and 
RT [GU139634-GU139688]. Approval of the study protocol was 
obtained from the Health, Safety, and Research Ethics Committee of 
the University of Venda, Thohoyandou.
Results
A total of 79 HIV-infected individuals were sequentially recruited. 
The mean age was 43.5 (18 - 69) years. The most important risk 
factor for HIV transmission was sexual intercourse (88.6%), but 
the questionnaire was not designed to determine whether this was 
heterosexual or homosexual. In 90% of the cases the most probable 
place of HIV infection was South Africa. Viral DNA was obtained for 
62 out of 79 (78%) individuals. Reliable nucleotide sequences were 
obtained for 57 PR genes and 55 RT genes. Using the Stanford and 
IAS guidelines, major drug-resistant mutations were detected in 2 
out of 57 subjects (3.5%) (95% CI 0.019796 - 0.119077). One primary 
NNRTI mutation (Y181C) and one major PI mutation (L33F) were Corresponding author: P Bessong (bessong@univen.ac.za)
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Aim. We studied the prevalence of resistance mutations in drug-
naïve HIV-infected individuals at the Bela-Bela treatment site 
to gather information on the presence of antiretroviral (ARV) 
drug-resistant viruses in drug-naïve populations, so as to improve 
treatment guidance.
Subjects and methods. Drug-naïve HIV-1-infected individuals were 
sequentially recruited between February 2008 and December 2008 
from individuals visiting the voluntary counselling and testing (VCT) 
services of the Bela-Bela HIV/AIDS Wellness Clinic. Viral subtyping 
was done by phylogenetic analysis; drug-resistant mutations 
were determined according to the Stanford HIV Drug Resistance 
Interpretation and the International AIDS Society-USA Guidelines.
Results. A drug-resistant mutation prevalence of 3.5% (95% 
confidence interval 0.019796 - 0.119077) comprising Y181C and 
L33F was observed; 98% of the viruses were HIV-1 subtype C on 
the protease (PR) and reverse transcriptase (RT) gene regions.
Conclusion. The prevalence of drug-resistant mutations in drug-
naïve persons may be low in Bela-Bela after 8 years of access 
to antiretroviral treatment (ART), and resistance testing before 
initiating treatment may not be needed.
S Afr Med J 2011;101:335-337. 
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detected in two different patients. No primary NRTI mutation was 
recorded. The detected mutations, nucleotide substitution, and their 
potential significance are shown in Table I.
Phylogenetic analysis of the PR and RT genes showed that 56/57 
(98.2%) of the isolates were HIV-1 subtype C on both gene regions. 
One isolate (08BBVCT31ZA) was HIV-1 subtype B on the PR and 
RT genes (phylogenetic trees not shown). Mean genetic distance for 
the PR sequences ranged from 0.0101 to 0.2035 and 0.0331 to 0.1377 
for the RT sequences. Considering the first 300 amino acids in the 
RT gene, sequence alignment showed that the consensus sequences 
of the test viruses were identical to the global subtype C consensus, 
except at 2 positions (V60I and Q174K). The consensus sequence 
differed from the global subtype B consensus at 17 positions (V35T, 
E36A, T39E, S48T, V60I, K122E, D123G, K173A, Q174K, D177E, 
T200A, Q207E, R211K, V245Q, A272P, K277R, and T286A). Amino 
acid alignment of the PR gene showed that the test consensus was 
identical to the global subtype C consensus, except at position I13T. 
It differed from the global subtype B consensus at 8 positions (T12S, 
I15V, L19I, M36I, R41K, H69K, L89M, and I93L).
Discussion
The development of drug resistance is an important attribute of HIV 
biology. An inevitable drawback of HAART is the emergence of drug-
resistant variants in patients under treatment, which complicates 
treatment options and hampers good prognosis. Antiretroviral 
therapy was started at the Bela-Bela Wellness Clinic about 8 years ago, 
within which time resistance could have possibly emerged. The low 
rate (3.5%) of drug-resistant mutations detected in this study is similar 
to reports in other parts of South Africa. Drug-resistance studies 
among naïve patients reported a prevalence in Gauteng Province in 
2002 and 2004 of 4.2%;5  in Cape Town of 2.5%;6 and  3.6% in Free 
State Province.7 Low levels (<5%), or the absence of drug-resistant 
mutations, have been reported in Zambia8 and Malawi.9 Higher rates 
have been reported in several developed countries with more than a 
decade of ART history.10,11
Low rates of ARV drug resistance are expected in developing 
countries because most patients start therapy on highly potent 
regimens, unlike in the developed world where ART scale-up began 
with resistance-associated monotherapy and one-class dual therapy. 
In this study, one primary NNRTI mutation (Y181C) was observed 
(Y181C mutation causes high-level resistance to nevirapine and 
delavirdine and low-level resistance to efavirenz), while no primary 
NRTI mutation was noted. This mutation occurred in a 40-year-old 
married woman. At the time of the investigation, the South African 
national drug regimen guideline stipulated the use of stavudine, 
lamivudine and efavirenz as first-line therapy for those who had 
never been exposed to ARVs, with nevirapine replacing efavirenz 
for women of child-bearing age.12 It is not clear whether the patient 
who harboured the Y181C mutation had been enrolled in a mother-
to-child transmission prevention programme in which nevirapine 
was used.
One major PI mutation (L33F) was detected. This mutation is 
classified as a major mutation by the Stanford Drug Resistance 
Interpretation Algorithm, and as a minor mutation by the IAS-USA 
guidelines (L33F mutation is selected by fosamprenavir/ritonavir, 
duranavir/ritonavir, lopinavir/ritonavir, atazanavir/ritonavir, and 
tipranavir/ritonavir, and contributes to resistance to these drugs).
Conclusion
This study indicates that the prevalence of drug-resistant HIV among 
the drug-naïve population in Bela-Bela is low after 8 years of free 
ART. We used population-based sequencing in our study, which 
might have contributed to an underestimation of drug-resistance 
prevalence. Patients may harbour populations of minor-resistance 
viruses that are usually not detected by population sequencing. This 
prevalence study also used chronically infected patients, which could 
mean that resistance acquired might have disappeared over time, 
which might have also led to an underestimation of the results.
Apparently, the testing of patients for drug-resistant viruses before 
initiation of therapy may not be required. However, subsequent 
periodic studies are required in Bela-Bela and other treatment sites 
to monitor the emergence and spread of drug-resistant viruses. Such 
data are important for guiding policy on sentinel surveillance and 
treatment algorithms. A high prevalence could indicate the need for 
regular sentinel surveillance or for baseline genotypic drug-resistance 
testing before treatment.
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